breast cancer

Galen Perdikis, MD, left, and G. Patrick Maxwell, MD.
June 3, 2024

Dedication to advancing breast reconstruction surgery for patients links Perdikis, Maxwell

Perdikis now holds the recently established G. Patrick Maxwell, M.D. Chair of the Department of Plastic Surgery at Vanderbilt University Medical Center.

By Lucie Alig
Abigail Lindsey Rich talks about her research poster with Vanderbilt-Ingram Cancer Center director Ben Ho Park, MD, PhD. (photo by Donn Jones)
May 30, 2024

Speakers share history of hereditary cancers at scientific retreat 

Speakers at the Vanderbilt-Ingram Cancer Center 25th Annual Scientific Retreat detailed the history of hereditary cancer discoveries and gave overviews about ongoing research. 

By Tom Wilemon
(iStock)
May 14, 2024

Breast cancer risk variants identified for women of African ancestry

A study led by researchers from Vanderbilt-Ingram Cancer Center sheds light on some of the genetic variants that make breast cancer more deadly for women of African ancestry and significantly reduces the disparity in knowledge for assessing their genomic risk factors.

By Tom Wilemon
March 8, 2024

Scalp cooling allows woman to keep hair during chemotherapy

The Food and Drug Administration first granted marketing approval for the DigniCap system for patients with breast cancer in 2015, then in 2017 the FDA expanded the authorization, making it the first cooling cap cleared for use in cancer patients with solid tumors, such as breast cancer, ovarian cancer and colorectal cancer.

By Tom Wilemon
Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)
December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

By Tom Wilemon
The study team included, from left, Paula Gonzalez-Ericsson, MD, Xiaopeng Sun, Justin Balko, PharmD, PhD, and Brandie Taylor, MS. (photo by Donn Jones)
October 4, 2023

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

By Tom Wilemon
July 26, 2023

International workgroup of geneticists issues CHEK2 guidelines

International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.
By Tom Wilemon
June 8, 2023

An image of cancer treatment response

An MRI method developed by Vanderbilt researchers uses imaging data to derive cell size and could be added to clinical practice for better monitoring of breast cancer treatment response.
By Sarah E. Glass
March 7, 2023

Nicole Kidman and Keith Urban gift supports breast cancer clinical trials at Vanderbilt-Ingram Cancer Center

Nicole Kidman and Keith Urban have made a generous financial gift to Vanderbilt-Ingram Cancer Center in support of clinical trials for new and better therapies for breast cancer.
By Tom Wilemon
February 16, 2023

Breast cancer genetics: new insights

Largest genetic study of breast cancer to date identifies 222 genetic risk loci, 137 genes and multiple signaling pathways associated with risk, providing important new insights.
By Leigh MacMillan
November 17, 2022

Surgery for hereditary breast cancer

Similar rates of bilateral mastectomy in women with inherited mutations in high- and moderate-penetrance genes raises concerns about possible overtreatment of some patients, Vanderbilt researchers report.
By Leigh MacMillan
August 11, 2022

Cell-free breast cancer “biopsy”

The circulating DNA that tumors release is a reliable metric of tumor genomics and can be used to monitor molecular changes in metastatic breast cancer.
By Sarah E. Glass
June 20, 2022

Five-year, multi-site trial to assess lymphedema prevention concludes

Lymphedema study results could be a game-changer for breast cancer patients and survivors. The Vanderbilt-led trial found that patients with early detection who used L-Dex with additional intervention were less likely to progress to chronic lymphedema than patients monitored with a tape measure receiving the same intervention. 
By Nancy Wise
1 2 3 … 12